Free Trial

Man Group plc Raises Stock Position in Genpact Limited (NYSE:G)

Genpact logo with Business Services background

Man Group plc boosted its position in shares of Genpact Limited (NYSE:G - Free Report) by 51.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 81,306 shares of the business services provider's stock after acquiring an additional 27,684 shares during the period. Man Group plc's holdings in Genpact were worth $3,492,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Blue Trust Inc. grew its stake in Genpact by 8.7% in the 4th quarter. Blue Trust Inc. now owns 5,531 shares of the business services provider's stock worth $217,000 after buying an additional 441 shares in the last quarter. KBC Group NV purchased a new position in Genpact in the 4th quarter worth approximately $298,000. State of New Jersey Common Pension Fund D purchased a new position in Genpact in the 4th quarter worth approximately $2,030,000. Pictet Asset Management Holding SA purchased a new position in Genpact in the 4th quarter worth approximately $921,000. Finally, Proficio Capital Partners LLC purchased a new position in Genpact in the 4th quarter worth approximately $983,000. Hedge funds and other institutional investors own 96.03% of the company's stock.

Insider Transactions at Genpact

In other news, Director Nicholas C. Gangestad purchased 2,000 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was bought at an average cost of $43.97 per share, for a total transaction of $87,940.00. Following the acquisition, the director now directly owns 2,000 shares of the company's stock, valued at $87,940. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Balkrishan Kalra sold 13,600 shares of the company's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $48.89, for a total transaction of $664,904.00. Following the sale, the chief executive officer now owns 310,246 shares of the company's stock, valued at $15,167,926.94. This represents a 4.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.07% of the company's stock.

Genpact Trading Up 1.1%

Shares of G traded up $0.49 during mid-day trading on Tuesday, reaching $44.00. The company's stock had a trading volume of 1,269,309 shares, compared to its average volume of 1,368,861. The stock has a market cap of $7.69 billion, a PE ratio of 15.49, a P/E/G ratio of 1.84 and a beta of 1.02. The company has a current ratio of 2.16, a quick ratio of 1.85 and a debt-to-equity ratio of 0.50. Genpact Limited has a 52 week low of $30.38 and a 52 week high of $56.76. The company's fifty day moving average price is $47.15 and its two-hundred day moving average price is $47.36.

Genpact (NYSE:G - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The business services provider reported $0.84 earnings per share for the quarter, topping analysts' consensus estimates of $0.80 by $0.04. The firm had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.21 billion. Genpact had a net margin of 10.77% and a return on equity of 22.50%. The business's quarterly revenue was up 7.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.73 EPS. On average, analysts predict that Genpact Limited will post 3.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on G. Mizuho boosted their price target on shares of Genpact from $45.00 to $55.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Needham & Company LLC cut their price target on shares of Genpact from $55.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. TD Cowen raised shares of Genpact from a "hold" rating to a "buy" rating and boosted their price target for the stock from $45.00 to $60.00 in a research note on Friday, February 7th. Finally, Robert W. Baird cut their price target on shares of Genpact from $56.00 to $50.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Genpact currently has an average rating of "Hold" and a consensus target price of $50.71.

View Our Latest Stock Analysis on G

About Genpact

(Free Report)

Genpact Limited provides business process outsourcing and information technology services in India, rest of Asia, North and Latin America, and Europe. It operates through three segments: Financial services; Consumer and Healthcare; and High Tech and Manufacturing. The Financial Services segment offers retail customer onboarding, customer service, collections, card servicing operations, loan and payment operations, commercial loan, equipment and auto loan, mortgage origination, compliance services, reporting and monitoring, and wealth management operations support; financial crime and risk management services; and underwriting support, new business processing, policy administration, claims management, catastrophe modeling and actuarial services, as well as property and casualty claims.

Recommended Stories

Institutional Ownership by Quarter for Genpact (NYSE:G)

Should You Invest $1,000 in Genpact Right Now?

Before you consider Genpact, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genpact wasn't on the list.

While Genpact currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Goldman Sachs Warns of 20% Market Drop—Are They Right?
3 Bank Stocks Defying Market Turmoil—Cheap Options Trades!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines